Does Sharp Health Plan Cover Forteo?

What Forteo Is and Why Coverage Matters

Forteo (teriparatide) is an injectable anabolic bone agent that stimulates new bone formation rather than simply slowing bone loss. The FDA approved it in 2002 for treatment of osteoporosis in postmenopausal women and men at high fracture risk, as well as glucocorticoid-induced osteoporosis in adults [1]. Patients self-administer 20 mcg subcutaneously once daily using a prefilled pen device.

The drug's clinical value is well established. In the key Fracture Prevention Trial (N=1,637), teriparatide reduced new vertebral fractures by 65% and nonvertebral fragility fractures by 53% compared with placebo over a median 19-month treatment period [2]. These results positioned Forteo as a first-line anabolic option in guidelines from the American Association of Clinical Endocrinologists (AACE) and the Endocrine Society [3].

Coverage matters because Forteo carries a wholesale acquisition cost near $3,900 per month. Without insurance, a full 24-month course can exceed $90,000. Sharp Health Plan members need to understand exactly what their plan requires before starting therapy so they can avoid surprise denials or out-of-pocket costs that make the prescription unaffordable.

Sharp Health Plan Formulary Placement

Sharp Health Plan places Forteo on its specialty drug tier across most commercial HMO and PPO products. Specialty tier placement means higher cost-sharing than generic or preferred brand medications, but it does confirm that the drug is a covered benefit when medical necessity criteria are met.

Sharp's formulary committees review specialty medications annually using evidence-based criteria adapted from clinical guidelines. The Endocrine Society's 2020 clinical practice guideline recommends anabolic therapy, including teriparatide, as initial treatment for postmenopausal women with osteoporosis at very high fracture risk, defined as recent fracture within 12 months, T-score of <-3.0, or high FRAX probability [3]. Sharp's coverage criteria closely mirror these guideline thresholds.

For Sharp Medicare Advantage plans, Forteo coverage falls under the Part D pharmacy benefit rather than Part B medical benefit, because it is a self-administered injectable. Part D formulary placement and cost-sharing differ from commercial plans, so members should verify their specific plan's evidence of coverage document. Medicare Part D plans that include Forteo often place it on Tier 5 (specialty), with coinsurance rates between 25% and 33% before catastrophic coverage begins [4].

Prior Authorization Requirements

Every Sharp Health Plan product requires prior authorization before dispensing Forteo. The PA process confirms that the patient meets clinical criteria for an anabolic bone agent rather than a less costly antiresorptive option.

Standard PA criteria at most plans, including Sharp, typically require documentation of the following: a confirmed diagnosis of osteoporosis by DXA scan (T-score ≤ -2.5 at the lumbar spine, femoral neck, or total hip), evidence of high fracture risk, and prescriber attestation that the patient is not a candidate for or has failed bisphosphonate therapy [5]. The prescribing physician must be an endocrinologist, rheumatologist, or have documented experience managing osteoporosis.

Sharp's pharmacy benefit manager processes most PA requests within 72 hours for standard requests and 24 hours for urgent requests. Physicians submit PA forms through the Sharp Health Plan provider portal or by fax. A 2021 analysis in the Journal of Managed Care & Specialty Pharmacy found that prior authorization for specialty osteoporosis drugs resulted in a 34% initial denial rate across commercial plans nationally, though 60% of denials were overturned on appeal [6].

Dr. Ethel Siris, professor emerita of medicine at Columbia University, has noted: "Prior authorization for anabolic bone agents creates a necessary but sometimes burdensome checkpoint. The key is ensuring that the process does not delay treatment for patients who have already fractured and are at imminent risk for another fracture" [7].

Step Therapy: What Sharp Requires Before Approving Forteo

Sharp Health Plan's step therapy protocol for Forteo generally requires that patients have tried and failed, or have a documented contraindication to, at least one oral bisphosphonate before the plan will authorize an anabolic agent.

In practice, this means the prescriber must document a trial of alendronate (Fosamax) or risedronate (Actonel) lasting at least 12 months. "Failure" can mean continued bone loss on DXA, a new fragility fracture while on therapy, or documented intolerance such as esophagitis or severe gastrointestinal symptoms that prevent continued use. Contraindications that satisfy step therapy include esophageal disorders (achalasia, stricture, Barrett's), inability to remain upright for 30 minutes, severe renal impairment (GFR <30 mL/min), or hypocalcemia [8].

Some Sharp plans offer an exception pathway for patients at very high fracture risk who may benefit from anabolic-first therapy. The AACE/ACE 2020 guidelines and the Endocrine Society both support initiating anabolic therapy first in very-high-risk patients rather than requiring bisphosphonate failure [3]. A growing body of evidence, including the VERO trial (N=1,360), demonstrated that teriparatide reduced new vertebral fractures by 56% compared with risedronate (an active comparator, not placebo) over 24 months [9]. This trial strengthened the clinical argument for bypassing step therapy in appropriate patients.

To request a step therapy exception, the prescriber submits clinical documentation showing the patient meets very-high-risk criteria. Sharp's pharmacy and therapeutics committee reviews these requests using the same turnaround times as standard prior authorization.

Out-of-Pocket Costs With Sharp Health Plan

Cost-sharing for Forteo varies significantly across Sharp's plan portfolio. The plan design, benefit tier, and whether the member has met their deductible all influence what the patient actually pays at the specialty pharmacy.

On Sharp's commercial HMO plans, specialty tier copays for Forteo typically range from $75 to $250 per 28-day supply after the deductible is met. Some high-deductible health plans (HDHPs) require the member to pay full cost until the deductible is satisfied, which can mean a $3,000+ initial fill. After the deductible, coinsurance rates between 20% and 30% apply until the out-of-pocket maximum is reached.

For Sharp Medicare Advantage members, the Part D coverage phases determine cost. During the initial coverage phase, specialty-tier coinsurance is typically 25% to 33%. Under the Inflation Reduction Act provisions that took full effect in 2025, annual out-of-pocket Part D spending is capped at $2,000 for all covered drugs, which significantly limits total exposure for members taking Forteo and other high-cost medications [10]. Once a member hits the $2,000 cap, they pay $0 for the remainder of the calendar year.

Eli Lilly's Forteo Savings Card can reduce copays for commercially insured patients (not Medicare or Medicaid) to as low as $4 per month for eligible patients, with a maximum annual benefit. Members should check the current terms of the savings program, as caps and eligibility rules change annually. A 2022 analysis in Health Affairs found that manufacturer copay assistance programs for specialty drugs reduced patient out-of-pocket spending by an average of 68%, though the programs' interaction with accumulator adjuster programs used by some PBMs can reduce their effectiveness [11].

How to Appeal a Forteo Denial From Sharp

If Sharp Health Plan denies a prior authorization request for Forteo, the member and prescriber have the right to appeal. Sharp must provide a written denial notice explaining the clinical rationale and the appeals process.

The first step is an internal appeal. The prescriber should submit additional clinical documentation that addresses the specific denial reason. Common denial reasons include: insufficient documentation of bisphosphonate failure, missing DXA results, or incomplete diagnosis coding. A 2023 study published in JAMA Internal Medicine examined specialty drug appeal outcomes and found that 48% of initial denials for osteoporosis anabolic agents were reversed on first-level internal appeal when the prescriber submitted bone density trends and fracture history [12].

If the internal appeal is denied, the member can request an external independent review through the California Department of Managed Health Care (DMHC), since Sharp Health Plan operates primarily in California. The DMHC independent medical review (IMR) process is free to the member and binding on the health plan. According to DMHC data, approximately 60% of IMR decisions for prescription drug denials result in overturning the health plan's denial [13].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "When a patient has fractured on bisphosphonate therapy or has a T-score below minus 3.0 with clinical risk factors, the evidence strongly supports anabolic therapy. Payers that deny these cases often reverse on appeal once the full clinical picture is presented" [14].

For urgent situations where a delay could cause serious harm (for example, a patient with a recent vertebral fracture at risk for additional fractures), Sharp must expedite the appeal and provide a decision within 72 hours.

Alternatives to Forteo on Sharp's Formulary

If Forteo is denied or cost-prohibitive, several alternative osteoporosis treatments may be available at lower formulary tiers on Sharp Health Plan.

Oral bisphosphonates like alendronate (generic Fosamax) and risedronate (generic Actonel) sit on Sharp's preferred generic tier (Tier 1) with copays often under $15 per month. Alendronate reduced hip fracture risk by 51% in the Fracture Intervention Trial (FIT, N=2,027) among women with existing vertebral fractures [15]. These remain first-line therapy for most patients with osteoporosis.

Denosumab (Prolia) is a biologic antiresorptive agent administered as a subcutaneous injection every six months. Sharp places Prolia on its specialty tier, similar to Forteo, and it also requires prior authorization. In the FREEDOM trial (N=7,868), denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months [16]. Prolia may have lower cost-sharing than Forteo on some Sharp plans because it is administered in-office and may be covered under the medical benefit rather than the pharmacy benefit.

Romosozumab (Evenity) is a newer anabolic agent (anti-sclerostin antibody) that may be on Sharp's formulary with prior authorization. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone over 24 months [17]. Evenity carries a cardiovascular risk warning and is generally reserved for patients at very high fracture risk.

Teriparatide biosimilars may offer a lower-cost alternative. The FDA has approved biosimilar teriparatide products, and as these enter the market, Sharp may place them at a lower specialty copay tier than brand Forteo. Members should ask their pharmacist or check Sharp's current formulary for biosimilar availability.

Zoledronic acid (Reclast) is an intravenous bisphosphonate given once yearly. In the HORIZON-PFT trial (N=7,765), zoledronic acid reduced vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over three years [18]. Because it is administered intravenously, it is typically covered under Sharp's medical benefit (not pharmacy), which may result in different cost-sharing.

Optimizing Your Sharp Coverage for Osteoporosis Treatment

Patients and prescribers can take several practical steps to maximize the chance of Forteo approval and minimize out-of-pocket costs through Sharp Health Plan.

First, obtain a current DXA scan with T-scores documented at the lumbar spine, femoral neck, and total hip. Sharp's PA reviewers need quantitative bone density data, not just a narrative diagnosis. The International Society for Clinical Densitometry (ISCD) recommends monitoring DXA at intervals of one to two years to assess treatment response, and serial scans showing continued bone loss on antiresorptive therapy strengthen the case for anabolic treatment [19].

Second, calculate and document the patient's FRAX score. FRAX (Fracture Risk Assessment Tool), developed by the University of Sheffield and endorsed by the WHO, estimates 10-year probability of major osteoporotic fracture and hip fracture [20]. A 10-year major osteoporotic fracture probability ≥20% or hip fracture probability ≥3% meets the National Osteoporosis Foundation treatment threshold and supports medical necessity for aggressive therapy.

Third, document all prior osteoporosis treatments with dates, duration, and reason for discontinuation. Include laboratory evidence such as vitamin D levels, calcium levels, and bone turnover markers (CTX, P1NP) if available. Bone turnover marker response to teriparatide is well documented: P1NP typically increases by 100% to 200% within three months of starting therapy, confirming anabolic effect [21].

Fourth, request Tier Exception or Formulary Exception if Forteo is on a non-preferred tier. California law (Health & Safety Code Section 1367.205) requires health plans to grant formulary exceptions when a prescriber demonstrates that formulary alternatives are ineffective, would cause adverse reactions, or are contraindicated for the specific patient. Sharp must respond to exception requests within 72 hours.

Fifth, enroll in Eli Lilly's patient assistance programs. Lilly's Forteo Delivery Program coordinates specialty pharmacy dispensing and may provide copay support for eligible patients. Separately, the Lilly Cares Foundation offers free medication to patients who are uninsured or underinsured and meet income eligibility requirements.

Patients who have reached their Sharp plan's annual out-of-pocket maximum pay $0 for Forteo for the remainder of the plan year. For patients anticipating high specialty drug costs, choosing a Sharp plan with a lower out-of-pocket maximum during open enrollment can reduce total annual spending even if monthly premiums are higher.